Sanfilippo Syndrome Market Report 2026

The sanfilippo syndrome market size has grown rapidly in recent years. It will grow from $9.21 billion in 2025 to $10.18 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to limited treatment options for sanfilippo syndrome, increasing recognition of lysosomal storage disorders, growth in rare disease advocacy groups, gradual improvement in diagnostic capabilities, early-stage research funding for orphan diseases.

The sanfilippo syndrome market size is expected to see rapid growth in the next few years. It will grow to $15.02 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to advancement of aav-based gene therapies, increasing orphan drug designations and incentives, rising healthcare expenditure on rare diseases, expanding newborn screening initiatives, growing investment from biotech and pharmaceutical companies. Major trends in the forecast period include increasing clinical trial activity for sanfilippo syndrome therapies, growing adoption of gene therapy approaches in pediatric neurodegenerative disorders, rising use of advanced diagnostic techniques for early detection, expanding compassionate use and early access programs for rare diseases, higher collaboration between biotech firms and research institutions.

The growing focus on gene therapies is expected to drive the growth of the sanfilippo syndrome market in the coming years. Gene therapies are medical treatments that modify or replace defective genes to treat or prevent diseases. This increasing focus is driven by the potential of gene therapies to address genetic disorders, rare diseases, and chronic conditions by targeting the underlying cause at the molecular level. In Sanfilippo syndrome, gene therapies work by delivering functional copies of the defective gene to restore enzyme production, thereby reducing the buildup of harmful substances in cells. For example, in April 2024, the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, reported that phase III gene therapy clinical trials increased by 10% in Q4 2023, marking the first quarterly rise since Q3 2022. Therefore, the expanding focus on gene therapies is driving growth in the sanfilippo syndrome market.

Key companies in the sanfilippo syndrome market are focusing on innovative treatments, such as gene therapies, to enhance patient outcomes and slow disease progression. Gene therapy uses genes to prevent, treat, or cure diseases by correcting or replacing faulty genes in the body. For instance, in February 2025, Ultragenyx Pharmaceutical Inc., a US-based biopharmaceutical company, announced new data on UX111 (ABO-102), an AAV gene therapy for Sanfilippo Syndrome Type A (MPS IIIA). The therapy showed statistically significant improvements in Bayley-III raw scores for cognition, receptive communication, and expressive communication. Additionally, it resulted in a substantial and sustained reduction in cerebrospinal fluid (CSF) heparan sulfate (HS) levels, which correlated with better clinical outcomes.

In April 2025, Spruce Biosciences, a US-based biopharmaceutical company, acquired the tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) from BioMarin Pharmaceutical Inc. for an undisclosed amount. Through this acquisition, Spruce aims to strengthen its rare-disease pipeline and focus on near-term commercial opportunities in MPS IIIB, addressing significant unmet needs with a development-ready asset. BioMarin Pharmaceutical Inc., based in the US, develops therapies for serious genetic and rare diseases, including enzyme replacement treatments for lysosomal storage disorders.

Major companies operating in the sanfilippo syndrome market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc, JCR Pharmaceuticals Co Ltd, Denali Therapeutics Inc, REGENXBIO Inc, Greenwood Genetic Center, ArmaGen Inc, Abeona Therapeutics Inc, Orchard Therapeutics plc, Allievex Corporation, Lysogene SA, Sio Gene Therapies Inc, Abeona Therapeutics Europe, Spark Therapeutics Inc, PTC Therapeutics Inc, Neurogene Inc, Taysha Gene Therapies Inc, MeiraGTx Holdings plc, Sangamo Therapeutics Inc, Freeline Therapeutics Holdings plc, LogicBio Therapeutics Inc.

North America was the largest region in the sanfilippo syndrome market in 2025. The regions covered in the sanfilippo syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sanfilippo syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the Sanfilippo syndrome market by increasing costs associated with imported biologics manufacturing equipment, viral vectors, and specialized laboratory instruments used in gene and enzyme replacement therapies. North America and Europe are most affected due to their reliance on cross-border supply chains for advanced biopharmaceutical components, while Asia-Pacific faces pricing pressures on research reagents. These tariffs can slow clinical development timelines and increase therapy costs. However, they are also encouraging localized manufacturing, domestic bioprocessing investments, and supply chain resilience in rare disease therapeutics.

The sanfilippo syndrome market research report is one of a series of new reports that provides sanfilippo syndrome market statistics, including sanfilippo syndrome industry global market size, regional shares, competitors with a sanfilippo syndrome market share, detailed sanfilippo syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the sanfilippo syndrome industry. This sanfilippo syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sanfilippo syndrome, also known as mucopolysaccharidosis type III (MPS III), is a rare genetic disorder caused by enzyme deficiencies that prevent the body from properly breaking down heparan sulfate, a complex sugar. This results in the accumulation of toxic substances in cells, primarily impacting the central nervous system. The condition is marked by progressive neurodegeneration, developmental delays, behavioral challenges, and a decline in motor and cognitive functions.

The main treatments for Sanfilippo syndrome include enzyme replacement therapy (ERT), gene therapy, genistein, and other approaches. Enzyme replacement therapy (ERT) provides the deficient or faulty enzymes to reduce the buildup of harmful substances in affected individuals. Diagnostic methods include glycosaminoglycan (GAG) analysis, genomic DNA sequencing, activity assays, and others, and these are used by various end users such as hospitals and research institutions.

The sanfilippo syndrome market consists of revenues earned by entities by providing services such as substrate reduction therapies (SRT), and other emerging treatment modalities and related diagnostic services, supportive care solutions, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The sanfilippo syndrome market also includes sales of antiepileptic drugs, sleep aids, and behavioral management medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.